Develops potential anesthetic-based drug treatments for patients with treatment-resistant depression and seeks licenses for legacy drug assets.
10-K for FY2025, filed Mar 31, 2026We focus on building a pipeline of innovative therapeutics to address serious neuropsychiatric disorders with significant unmet medical…View ↗
CYC-126 consists of two generic intravenous anesthetic agents, propofol and dexmedetomidine, administered through a personalized delivery…View ↗
We were founded in 2018 to focus on the treatment of serious diseases with novel sGC stimulators in both the central nervous system (CNS)…View ↗
The company earns money from licensing drug rights through upfront and milestone payments and royalties; it also sells development materials and collects fees for options to license drug candidates.
10-K for FY2025, filed Mar 31, 2026On June 3, 2021, we entered into a License Agreement with Akebia (the “Akebia License Agreement”) relating to the exclusive worldwide…View ↗
On December 13, 2024, we announced that Cyclerion and Akebia re-negotiated a mutually beneficial amendment to Akebia's exclusive license…View ↗
In September 2025, we entered in a Material Purchase Agreement (the “Purchase Agreement”) with Akebia relating to purchase additional…View ↗
Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July 22, 2024, we entered into an Option to License…View ↗
10-K for FY2025, filed Mar 30, 2026
FY2025 revenue by product or service ↗$2.1M
10-K for FY2025, filed Mar 30, 2026
$2.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Revenue from license agreement
Licensed
10-K for FY2025, filed Mar 31, 2026 |
48% |
Revenue from license agreement, FY2025
$1M Sources
|
Licensed |
|
Revenue from purchase agreement
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
39% |
Revenue from purchase agreement, FY2025
$800K Sources
|
Sold outright |
|
Revenue from option agreement
Licensed
10-K for FY2025, filed Mar 31, 2026 |
13% |
Revenue from option agreement, FY2025
$274K Sources
|
Licensed |
Akebia pays directly under the praliciguat license and for development materials; a third-party optionee paid fees for an option to license olinciguat.
10-K for FY2025, filed Mar 31, 2026On June 3, 2021, we entered into a License Agreement with Akebia (the “Akebia License Agreement”) relating to the exclusive worldwide…View ↗
In September 2025, we entered in a Material Purchase Agreement (the “Purchase Agreement”) with Akebia relating to purchase additional…View ↗
Olinciguat is a Phase 2, orally administered, once-daily, vascular sGC stimulator. On July 22, 2024, we entered into an Option to License…View ↗
No. It lost $3.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$46.4MView ↗
8-K, filed Sep 11, 2026
Immediately prior to the closing of the merger, Korsana completed a previously announced private financing of $380 million in gross…View ↗
Shrinking. Revenue fell 47% in 4 years, from $3.9M in FY2021 to $2.1M in FY2025, about 15% a year.
Focus on depression treatment
The older report described drug candidates for several disease areas. The latest report centers development on an anesthetic-based approach for treatment-resistant depression.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 31, 2026
Legacy drug assets
The older report presented central nervous system drug candidates as part of the development portfolio; the latest report says some legacy assets were sold, internal research on that drug class stopped, and remaining assets may be licensed.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 31, 2026We were founded in 2018 to focus on the treatment of serious diseases with novel sGC stimulators in both the central nervous system (CNS)…View ↗
Competes with Johnson & Johnson, Eli Lilly, AbbVie, Pfizer, Novartis, Compass Pathways, and Axsome Therapeutics
10-K for FY2025, filed Mar 31, 2026TRD is a disease with high unmet need and is associated with multiple serious public health implications. The FDA and the EMA have adopted…View ↗
Loading...